Palantir Technologies Q2 earnings Send PLTR Stock Above $140 as Revenue Growth Accelerates
Palantir shares have surged around 10% in after-hours trading toward $140 after delivering exceptionally strong second-quarter growth, although the stock's elevated valuation and regulatory and international risks remain important considerations.
Quick overview
- Palantir shares surged approximately 10% in after-hours trading, reaching near $140 following strong second-quarter results.
- US commercial revenue increased by 149% year over year, contributing significantly to the overall revenue growth of 94%.
- Despite the positive earnings report, Palantir faces regulatory scrutiny in the UK and challenges in international expansion.
- The company's elevated valuation remains a concern, as future growth must continue to meet high investor expectations.
Palantir shares have surged around 10% in after-hours trading toward $140 after delivering exceptionally strong second-quarter growth, although the stock’s elevated valuation and regulatory and international risks remain important considerations.
Palantir Stock Rebounds Toward $140
Palantir Technologies shares have staged a powerful after-hours rebound after the company delivered significantly stronger-than-expected second-quarter results.
The stock jumped around 10% after the August 3 earnings release, moving toward the $140 level after previously coming under renewed pressure and approaching the $100 area.
The recovery represents a sharp change in sentiment. Before the earnings report, investors were increasingly concerned about Palantir’s demanding valuation, regulatory scrutiny surrounding its UK NHS contract and uncertainty surrounding its international expansion strategy.
The latest results have temporarily shifted attention back toward the company’s exceptional growth.
However, the magnitude of the rebound also means expectations are likely to become even higher. Investors will now need to determine whether Palantir can maintain this pace of expansion long enough to justify its premium valuation.
US Commercial Revenue Surges 149%
The strongest headline from the quarter was Palantir’s performance in the US commercial market.
US commercial revenue increased 149% year over year to $764 million, demonstrating that demand for the company’s software is expanding rapidly beyond its traditional government customer base.
Overall revenue increased 94% year over year, reaching approximately $1.94 billion. Revenue growth in the US was even stronger, rising 115%.
US government revenue also remained a major contributor, increasing 90% year over year to approximately $809 million.
Approximately $370 million of revenue came from international contracts, highlighting the continued importance of Palantir’s overseas business despite growing questions about its ability to expand into certain foreign government markets.
The company also reported adjusted earnings per share of $0.41, while adjusted income from operations reached approximately $1.19 billion.
Deal Activity Provides Another Positive Signal
Palantir’s contract activity offered another reason for investors to remain optimistic.
The company closed 220 deals worth at least $1 million during the second quarter. Of those, 98 were valued at $5 million or more, while 73 reached at least $10 million in total contract value.
Perhaps more importantly, Palantir’s remaining US commercial deal value climbed to approximately $6.238 billion, representing a 124% increase from a year earlier.
That figure provides an important indication of future commercial demand.
If Palantir can convert a substantial portion of this remaining contract value into revenue, the company’s commercial growth trajectory could remain strong for some time.
CEO Alex Karp also argued that demand for AI sovereignty is accelerating, positioning Palantir as a platform capable of helping organizations retain greater control over their operations, data and AI-related decisions.
Guidance Moves Higher
Palantir’s outlook also strengthened following the strong quarter.
For the third quarter, the company expects revenue of approximately $2.16 billion and adjusted income from operations above $1.29 billion.
The raised guidance provides investors with additional evidence that the acceleration in demand is not limited to a single quarter.
Still, the market reaction will eventually depend on whether Palantir can continue exceeding increasingly ambitious expectations.
The company’s share price already reflects a substantial amount of future growth, meaning even strong results could eventually fail to support the valuation if growth begins to moderate.
Technical Breakdown Raises the Stakes
Technically, the picture is getting weaker. Palantir broke below key support levels, including the 100-week simple moving average in green, which had previously acted as a stabilizing floor and is now facing the last technical support.
PLTR Chart Weekly – MAs Turn into Resistance
Former support zones have now turned into resistance, making near-term recoveries more difficult. Last week’s rebound took PLTR stock closer to the 100 SMA above $136 level which was the real test for buyers, but they failed at resistance again and PLTR fell to the 200 daily SMA (purple) which came under attack on the daily chart. However the price has rebounded above it again now.
PLTR Chart Daily – Reversing After the Doji Candlestick
NHS Contract Faces Regulatory Scrutiny
Despite the impressive earnings report, Palantir still faces regulatory uncertainty in the United Kingdom.
The UK’s Office for Statistics Regulation has raised concerns involving the communication of NHS England performance data associated with the Federated Data Platform.
The platform is an important part of NHS England’s digital infrastructure, connecting patient information, clinical records, workflow data and operational information across hospital trusts.
Palantir’s involvement has attracted considerable attention because the project represents an important demonstration of the company’s ability to deploy its technology within a major healthcare system.
The regulatory scrutiny does not mean the contract is being terminated.
Nevertheless, any changes to how information is presented, managed or communicated could potentially affect implementation requirements and timelines.
For investors, the issue is therefore less about an immediate loss of revenue and more about whether regulatory developments could complicate Palantir’s broader healthcare expansion.
International Expansion Remains Uncertain
Palantir’s international strategy also presents challenges.
European governments are increasingly focused on technological sovereignty, particularly when dealing with sensitive defence, intelligence and national-security applications.
Reports that French intelligence agencies could potentially reduce their reliance on Palantir software in favour of domestic alternatives have therefore raised questions about the company’s ability to replicate its US success overseas.
The financial impact may remain limited in the near term, but the strategic implications could be more significant.
If European governments increasingly prioritize locally developed technology, Palantir could face longer sales cycles, greater competition and higher costs when attempting to secure international contracts.
That would not necessarily undermine the company’s broader growth story, but it could make international expansion less predictable.
Valuation Remains the Biggest Risk
Palantir’s biggest vulnerability remains its valuation.
The company’s exceptional revenue growth, expanding commercial customer base and exposure to AI have caused investors to assign a substantial premium to the shares.
That premium can work in Palantir’s favor when growth exceeds expectations, as demonstrated by the latest after-hours rally.
But it can also work against shareholders when expectations are missed.
At elevated valuations, investors typically demand continued acceleration in revenue, expanding margins, strong contract momentum and optimistic guidance.
Any meaningful slowdown could therefore trigger an outsized reaction.
The recent decline toward $100 demonstrated how quickly sentiment can change when investors begin questioning whether the valuation has moved too far ahead of fundamentals.
Conclusion: Strong Earnings, Higher Expectations
Palantir’s latest earnings report provides a powerful fundamental argument for the stock.
US commercial revenue surged 149%, total revenue increased 94%, contract activity remained exceptionally strong and remaining US commercial deal value climbed to more than $6.2 billion.
The upgraded third-quarter outlook further strengthens the case that Palantir’s growth remains substantial.
The 10% after-hours rally toward $140 therefore reflects genuine improvement in the company’s operating picture.
However, the recovery does not eliminate the risks.
Palantir remains highly valued, while regulatory scrutiny in the UK and uncertainty surrounding international government contracts could create additional challenges. More importantly, the stronger the stock rallies, the higher the expectations become.
For now, the earnings report has shifted the immediate narrative decisively back toward growth. The next challenge for Palantir will be proving that its extraordinary commercial momentum can remain strong enough to justify an increasingly demanding valuation.
- Check out our free forex signals
- Follow the top economic events on FX Leaders economic calendar
- Trade better, discover more Forex Trading Strategies
- Open a FREE Trading Account
- Read our latest reviews on: Avatrade, Exness, HFM and XM
Related Articles
Sidebar rates
Related Posts
SaveAva
